NeoGenomics Q1 revenue up 11% to $187M; raises FY2026 guidance to $797-803M

NEOGENOMICS INC

Consolidated revenue $187M (+11% YoY); Clinical revenue +14%, NGS +26%.
Net loss narrowed 34% to $17M; adjusted EBITDA $9M (+27% YoY).
Raised FY2026 revenue guidance to $797-803M (prior range not specified).
Launched RaDaR ST MRD assay; received MolDX coverage for PanTracer LBx.
Cash and marketable securities $146M at quarter end.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NEOGENOMICS INC reported first quarter of 2026 results: revenue $187 million, net income $17 million. Guidance raised.

Period: first quarter of 2026
Revenue: $187 million
Net income: $17 million
Guidance: raised
Result: reported results

Exact text from the filing

Consolidated revenue for the first quarter of 2026 was $187 million, an increase of 11% over the same period in 2025.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NEOGENOMICS INC reported full-year 2026 results: revenue $797-$803 million. Guidance raised.

Period: full-year 2026
Revenue: $797-$803 million
Guidance: raised
Result: guidance update

Exact text from the filing

Company announces increase in full-year 2026 revenue guidance to a range of $797-$803 million

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

NEOGENOMICS INC filing history →

Source: SEC EDGAR

accession 0001077183-26-000022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.